Protalix, Chiesi Global Rare Diseases: EC approves dosing regimen for Elfabrio

Chiesi Global Rare Diseases and Protalix (PLX) BioTherapeutics announced that the European Commission has approved the 2mg/kg every-4-weeks dosing regimen for Elfabrio in adults living with Fabry disease who are stable with an ERT. The EC decision follows the positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending the additional dosing regimen.